Skip to main content
ARWR logo

ARWR · Arrowhead Pharmaceuticals, Inc.

Track ARWR — free
$41.37 -2.28 (-5.22%) At close · Nov 20
Market Cap
$5.85B
Shares
141.37M
Volume · Nov 20 3.91M Avg daily vol (3M) 2.07M

Price & Indicators

 

Key stats

Close
$41.37
Fri 20 Nov
Open
$43.15
Fri 20 Nov
Average volume, 30 days
2.2M
shares a session
Short interest
11.6M
8.2% of shares · 8.5 days to cover
Day range
$41.17$44.80
Open $43.15 Close $41.37
52-week closing range
$38.09$89.59
Close $41.37 53.8% under the high
Short volume, last session
38%
Last earnings
Nov 12, 2026
Latest filing
10-K · Nov 12
Price history
Jan 2020 to Nov 2026

Up next

Feb 4, 2027 Est · unconfirmed · in 11 wks

Latest documents

2026
Nov 18
Investor event
Redemplo SNDA filed for severe hyperglyceridemia; approval possibly March-April

The CEO said the Redemplo sNDA for severe hyperglyceridemia was filed November 2nd, with approval possible within six months, perhaps in March-April. Redemplo lowered triglycerides by 80% from baseline, is dosed once a quarter, and carries a list price of $45,000 a year.

6 source passages
We just filed our SNDA to expand that to include severe hyperglyceridemia. The SNDA was filed November 2nd, and so sometime up to six months from then. We have star designation, so we expect that to be approved in the March-April time frame or so. we see 80% reduction from baseline of triglycerides this is dosed once a quarter. Our list price is $45,000 a year. Open the document at this passage
Nov 12
Earnings call
SHTG launch targeted as fiscal loss reaches $724.2 million

Arrowhead Pharmaceuticals targets a potential U.S. SHTG launch in the second quarter of 2027 after reporting fiscal 2026 revenue of $450.8 million and a net loss attributed to the company of $724.2 million.

Read from the first part of this long document
4 source passages
welcome to the Arrowhead Pharmaceuticals conference call. Then I'll connect them to our planned SHTG launch anticipated in the second calendar quarter of 2027. Revenue for fiscal year 2026 totaled $450.8 million compared to $829.4 million in fiscal 2025. As we reported today, net loss attributed to Arrowhead for fiscal year 2026 was $724.2 million, or loss of $5.11 per share, based on $141.6 million fully valued weighted average shares outstanding in the year. Open the document at this passage
Nov 12
Annual report 10-K FY2026, ended Sep 30
REDEMPLO launches as plozasiran advances toward U.S. launch

Arrowhead launched REDEMPLO after November 18, 2025 approval and is preparing a second-quarter 2027 U.S. launch of plozasiran. Phase 3 studies showed 79% and 81% triglyceride reductions; the company raised $930.0 million through convertible notes, stock and pre-funded warrants.

Revenue $450.82M ▼ 45.6% Net loss $724.21M Diluted EPS -$5.11
Read from the MD&A section
6 source passages
On November 18, 2025, the FDA approved the Company's New Drug Application (NDA) for REDEMPLO injection for FCS. After receiving regulatory approval for REDEMPLO in the United States in November 2025, the Company launched the product and began recognizing product revenue. The Company has submitted an sNDA to the U.S. FDA and is currently preparing for a potential U.S. launch in sHTG in the second quarter of 2027, pending successful regulatory filing, review, and approval, and plans to seek regulatory approval with additional global regulatory authorities thereafter. Plozasiran reduced triglycerides (TG) by 79% and 81% versus placebo in SHASTA-3 and SHASTA-4 across the broad sHTG population. On January 8, 2026, the Company completed upsized offerings of 0.00% convertible senior notes, common stock, and pre-funded warrants with gross proceeds of $930.0 million, which strengthened the Company's balance sheet. With these interim topline results, Arrowhead’s innovative and proprietary TRiM platform has achieved clinical validation of its ability to target and silence two genes simultaneously in one molecule. Open the document at this passage
Nov 12
Current report 8-K
REDEMPLO prescriptions rise 63% amid sNDA submission

Arrowhead Pharmaceuticals reported 63% quarter-over-quarter growth in new-to-brand REDEMPLO prescriptions, submitted plozasiran’s sNDA for severe hypertriglyceridemia, and established a new $400 million senior secured term loan facility maturing in November 2031.

Financial results
6 source passages
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its 2026 fiscal year ended September 30, 2026. New to brand REDEMPLO prescriptions grew by 63% quarter over quarter. Submitted sNDA to FDA for plozasiran and preparing for a potential U.S. launch in sHTG in the second quarter of 2027, pending successful regulatory filing, review, and approval. Announced that the U.S. Food and Drug Administration (FDA) had granted plozasiran entry in the Split Real Time Application Review (STAR) pilot program in connection with Arrowhead’s supplemental new drug application (sNDA) for severe hypertriglyceridemia (sHTG). Refinanced an existing credit facility with Sixth Street and established a new $400 million senior secured term loan facility with several important benefits: The new facility matures in November 2031. Open the document at this passage
Nov 4
Current report 8-K
Refinancing lowers borrowing costs and extends debt maturity

Arrowhead Pharmaceuticals refinanced its senior secured term loans with Sixth Street, obtaining a fully funded $400.0 million facility maturing November 2, 2031; it has no scheduled amortization and eliminates required revenue and transaction-proceeds sweeps.

Entered into a material agreement, New debt or off-balance-sheet obligation
3 source passages
On November 2, 2026 (the “Closing Date”), Arrowhead Pharmaceuticals, Inc. (the “Company”) and its subsidiary, Arrowhead Madison Inc., as guarantor, refinanced its senior secured term loans under the Existing Financing Agreement (defined below) by entering into an Amended and Restated Financing Agreement (the “A&R Financing Agreement”) with the lenders party thereto (the “Lenders”) and Sixth Street Lending Partners, as administrative agent and collateral agent for the Lenders (“Sixth Street”). The A&R Financing Agreement provides for a senior secured term loan facility in an aggregate principal amount of $400.0 million (the “Credit Facility”), which was fully funded on the Closing Date. The Credit Facility matures on November 2, 2031 (the “Maturity Date”) and bears interest, at the Company’s election, at an annual rate equal to three-month Term SOFR (subject to a 1.00% floor) plus 5.50% or a base rate (subject to a 2.00% floor) plus 4.50%. Unlike the Existing Financing Agreement, the A&R Financing Agreement does not require the Company to prepay the Credit Facility with any portion of net sales of plozasiran or other products, royalties, milestones or other proceeds of licensing or partnering transactions, or proceeds of pipeline asset monetizations. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$450.82M
Trailing 12 months
Net income (TTM)
−$716.80M
Trailing 12 months
Revenue growth YoY
-85.3%
Year over year
Operating margin
-156.9%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-4.9%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$62.73M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+3.1%
Year over year · more shares
Price change (1Y)
+8.6%
Trailing year
Short interest
8.2%
Latest settlement · 8.5 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Aug 4, 2026
Q3 FY26

TL;DR. Arrowhead reported positive SHASTA-3 and SHASTA-4 Phase 3 topline results supporting a plozasiran sNDA in SHTG, acquired a priority review voucher to accelerate that submission, and continued to expand REDEMPLO's commercial footprint in FCS including EU and Australia approvals, while net loss widened to $194.3M and operating expenses rose year-over-year.

Bullish
  • + SHASTA-3 and SHASTA-4 both met primary and all pre-specified secondary endpoints with 79% and 81% median triglyceride reductions
  • + Plozasiran reduced acute pancreatitis events by 78% across SHTG and 100% in the highest-risk subgroup
  • + REDEMPLO received marketing authorization in the EU and Australia, expanding approved footprint to five geographies
  • + Madrigal license deal brings $25M upfront plus up to $975M in milestones and tiered royalties
  • + Cash and investments of approximately $1.6 billion provide funding flexibility
Bearish
  • − Net loss widened to $194.3M ($1.36/share) from $175.2M a year ago
  • − Total operating expenses rose ~$52M year-over-year to $245M, with R&D up ~$36M and SG&A up ~$16M
  • − Pre-specified MRI-PDFF subgroup showed no statistically significant difference in liver fat between plozasiran and placebo

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Bearish Fundamentals Poor Quant / Vol Very High
Market backdrop VIX 35.9 · fear Equity put/call 0.62
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −41%
below
Price vs 50-day avg −30%
below
RSI (14) 21
oversold
MACD trend Negative
52-week position 6%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −29%
trailing
6-month return −42%
trailing
YTD return −38%
this year
Relative strength −32%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $59 › 200d $70 — 200d above 50d
Institutional flow Distributing
-4% holders QoQ · +66 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
8.19% of shares out · ▲ +5.7% MoM · 8.5 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Steady
494 holders — mid 3-yr range
Squeeze score 61
elevated · 0–100
Fundamentals
Poor
Revenue growth −49%
Y/Y
EPS growth −51000%
Y/Y
Free cash flow $-283.9M
Quant / Vol
risk profile
Very High
Volatility 64%
annualized · 1-yr
Max drawdown −54%
past year
ATR 7.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed Nov 12, 2026
U.S. wholesale acquisition cost · if the broader indication is approved $45,000
Prior guidance period ended · from the Earnings Call filed Aug 4, 2026
Payment to the current holder for the FDA priority review vouche · fiscal fourth quarter $215M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−41% Bearish
Price vs 50-day avg
−30% Bearish
RSI (14)
21 Neutral
MACD trend
Negative Bearish
52-week position
6% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $59 › 200d $70 — 200d above 50d
Institutional flow Distributing
-4% holders QoQ · +66 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
8.19% of shares out · ▲ +5.7% MoM · 8.5 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Steady
494 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $38 Now $41 · 6% Range high $90
vs 200-day avg -41% vs 50-day avg -30%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Candidate costs 443.22M Year Ended September 30, 2026 filing —
Cumulative new to brand REDEMPLO prescriptions 950 as of the end of quarter —
Discovery costs 78.84M Year Ended September 30, 2026 filing —
More than 640 unique practitioners had prescribed REDEMPLO 640 as of the end of quarter —
Total research and development expense, excluding non-cash expense 683.36M Year Ended September 30, 2026 filing —
Total selling, general and administrative expense, excluding non-cash expense 163.24M Year Ended September 30, 2026 filing —
Amortization of debt issuance costs 767K the three months ended June 30, 2026 filing —
Total cash resources 1.57B June 30, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ARWR
Arrowhead Pharmaceuticals, Inc.
this stock
$5.85B -37.7% -48.6% — 8.2%
VRTX
Vertex Pharmaceuticals Inc
$130.58B +13.6% +46.2% 33.2 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.24B +19.3% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$78.90B +561.2% +4.3% — 8.2%
CSLLY
Csl Ltd
$62.17B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
494
% held
83.2%
Net QoQ
-2.0M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
487
View
Short & Settlement
Short Interest Rising
Shares short
11.6M
Days to cover
8.5d
Change
+624.2K sh
View
Short Volume
Short vol %
38%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
540
Value
$33.2K
As of
Oct 8, 2026
View
Off-Exchange
Off-exchange %
47.2%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Sell
Member
Daniel Goldman
Amount
$1.0K–$15.0K
Traded
Jan 31, 2023
View
Financials
Financials
Revenue (FY)
$450.8M
Net income (FY)
$-724.2M
EPS diluted
$-5.11
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 18, 2026
This year
23

The CEO said the Redemplo sNDA for severe hyperglyceridemia was filed November 2nd, with approval possible within six months, perhaps in March-April. Redemplo lowered triglycerides by 80% from baseline, is dosed once a quarter, and carries a list price of $45,000 a year.

View
Proposed Sales
Value
$641.9K
Shares
10.0K
Filed
Mar 5, 2026
View
Earnings & Events
Webcasts Upcoming
Next webcast
Dec 2, 2026
Last webcast
Nov 18, 2026
View
Investor Relations
Latest news
Arrowhead Pharmaceuticals Reports…
Published
Nov 17, 2026
Upcoming events
2
View

Performance

5D 20D 120D MTD YTD
ARWR -13.4% -28.7% -41.6% -30.9% -37.7%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY -4.9% -19.5% -32.4% -22.2% -38.9%
Key facts CIK 879407 CUSIP 04280A100 13F (30d) 467 filings 442 filers Visit website Investor relations